Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of escalating intravenous or oral BAL8557 (isavuconazonium sulfate) for antifungal prophylaxis in neutropenic AML patients
2005-005294-30Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of isavuconazonium in acute myeloid leukemia (AML), neutropenia and invasive mycoses (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Primary safety and tolerability endpoint. Started Feb 2006; status: completed.
02
Drugs
isavuconazonium
03
Conditions
acute myeloid leukemia (AML)neutropeniainvasive mycoses
Beyond the preview
Go deeper on 2005-005294-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005294-30.